Nebenwirkungen · Besponsa
BESPONSA 1 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10–11
HOS-135299 · Präparat HOS-097690
Infections and infestations Infectiona (48%) (includes Sepsis and Bacteraemia) [17%], Fungal infection [9%], Lower respiratory tract infection [12%], Upper respiratory tract infection [12%], Bacterial infection [1%], Viral infection [7%], Gastrointestinal infection [4%], Skin infection [4%] Blood and lymphatic system Febrile neutropenia (26%) Pancytopeniab (2%) disorders Neutropenia (49%) Thrombocytopenia (51%) Leukopenia (35%) Lymphopenia (18%) Anaemia (36%) Immune system disorders Hypersensitivity (1%) Metabolism and nutrition Decreased appetite (12%) Tumour lysis syndrome (2%) disorders Hyperuricaemia (4%) Nervous system disorders Headache (28%) Vascular disorders Haemorrhagec (33%) (includes Central nervous system haemorrhage [1%], Upper gastrointestinal haemorrhage [6%], Lower gastrointestinal haemorrhage [4%], Epistaxis [15%]) Gastrointestinal disorders Abdominal pain (23%) Ascites (4%) Vomiting (15%) Abdominal distension (6%) Diarrhoea (17%) Nausea (31%) Stomatitis (13%) Constipation (17%) Hepatobiliary disorders Hyperbilirubinaemia (21%) VOD/SOS (3% [pre-HSCT]d) Increased transaminases (26%) 10 Table 5. Adverse reactions reported in adult patients with relapsed or refractory B-cell precursor ALL who received BESPONSA
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-05-18T14:13:00Z · SHA-256 1da1da098efc99e357cf89eb2defe860d1474c0a37df3a9adcb8ba63218e0f18 · Passage 252dba7dcb33e517ae2c7716fbe7c9d7af4176bedc58c2ac145bb43166b2ff23 · Zeichen 1529–4053 im Abschnitt